Cost effectiveness of preventive screening programmes for type 2 diabetes mellitus in germany

Applied Health Economics and Health Policy

Volumn 8, Issue 3, 2010, Pages 191-202

  Schaufler, Thilo M ^a   Wolff, Malte ^a  

^a UNIVERSITY OF MANNHEIM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN;

ADULT; ARTICLE; BLINDNESS; COST EFFECTIVENESS ANALYSIS; FEMALE; GERMANY; HEART INFARCTION; HUMAN; INCIDENCE; KIDNEY FAILURE; LIFESPAN; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; MEDICAL EXAMINATION; NON INSULIN DEPENDENT DIABETES MELLITUS; ONSET AGE; POPULATION RESEARCH; PREVENTIVE MEDICINE; PROPHYLAXIS; QUALITY OF LIFE; SCREENING; STROKE; SYMPTOM;

COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; GERMANY; HUMANS; MARKOV CHAINS; MASS SCREENING; NATIONAL HEALTH PROGRAMS; QUALITY-ADJUSTED LIFE YEARS;

EID: 77951644766     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.2165/11532880-000000000-00000     Document Type: Article

References (45)

1. Organisation for Economic Co-Operation and Develop-ment. OECD health data 2008: statistics and indicators for 30 countries. CD-ROM version [online]. Available from URL http://www.oecd.org/health/healthdata [Accessed 2010 Mar 22]
2. Sachverstandigenrat fur die Konzertierte Aktion im Gesundheitswesen. Finanzierung, Nutzerorientierung und Qualitat. Baden-Baden: Nomos, 2003
3. Advisory Council on the Assessment of Developments in the Health Care System. Report 2007: cooperation and responsibility. Prerequisites for target-oriented health care [summary; online]. Available from URL http://www.svr-gesundheit.de/Gutachten/Gutacht07/KF2007-engl.pdf [Accessed 2010 Mar 22]
4. Blech J. Die Krankheitserfinder. Wie wir zu Patienten ge-macht werden. Frankfurt/Main: S. Fischer, 2003
5. Glumer C, Yuyun M, Griffin S, et al. What determines the cost-effectiveness of diabetes screening? Diabetologica 2006; 49: 1536-1544
6. CDC Diabetes Cost-Effectiveness Study Group. The cost-effectiveness of screening for type 2 diabetes [published erratum appears in JAMA 1999; 281 (4): 325]. JAMA 1998; 280 1757-1763
7. Clarke PM, Gray AM, Briggs A, et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS 68). Diabetologia 2004; 47: 1747-1759
8. Icks A, Haastert B, Gandjour A, et al. Cost-effectiveness ana-lysis of different screening procedures for type-2-diabetes: the KORA Survey 2000. Diabetes Care 2004; 27: 2120-2128
9. Zhou H, Isaman D, Messinger S, et al. A computer simula-tion model of diabetes progression, quality of life, and cost. Diabetes Care 2005; 28: 2856-2863
10. Zhang P, Engelau M, Valdez R, et al. Cost of screening for pre-diabetes among US adults: a comparison of different screening strategies. Diabetes Care 2003; 26: 2536-2542
11. Eastman RC, Javitt JC, Herman WH, et al. Model of com-plications of NIDDM: I. Model construction and assumptions. Diabetes Care 1997; 20: 725-734
12. Casciano R, Walzer S, Muller E. Krankheitsmodell am Beispiel Diabetes. Das EAGLE-Modell. Gesundh okon Qual Manag 2005; 10 Suppl. 2: S64-9
13. Palmer AJ, Roze S, Valentine W, et al. The CORE diabetes model: projecting long-term clinical outcomes, costs, and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004; 20 Suppl. 1: S5-26
14. Kanavos P, Mossialos E. Outstanding regulatory aspects in the European pharmaceutical market. Pharmacoeconom-ics 1999; 15 (6): 519-533
15. WHO. Definition, diagnosis and classification of diabetes mellitus and its complications. Geneva: WHO, 1999
16. Federal Office of Statistics, editors. Population statistics by sex and age groups: microcensus. Wiesbaden: Federal Office of Statistics, 2006
17. Rathmann W, Haastert B, Icks A, et al. High prevalence of undiagnosed diabetes mellitus in Southern Germany: target populations for efficient screening. The KORA Survey 2000. Diabetologia 2003; 46: 182-189
18. Lowel H, Stieber J, Koenig W, et al. Das diabetesbedingte Herzinfarktrisiko in der suddeutschen Bevolkerung. Er-gebnisse der MONICA-Augsburg-Studien 1985-1994. Diab Stoffw 1999; 8: 11-21
19. Kaarisalo MM, Raiha I, Sivenius J, et al. Diabetes worsens the outcome of acute ischemic stroke. Diabetes Res Clin Pract 2005; 69: 293-298
20. Liebl A, Neiss A, Spannheimer A, et al. Complications, co-morbidity, and blood glucose control in type-2-diabetes mellitus patients in Germany: results from the CODE 2 study. Exp Clin Endocrinol Diabetes 2002; 110: 10-16
21. Shearer A, Scuffham P, Gordois A, et al. Predicted costs and outcomes from reduced vibration detection in people with diabetes in the US. Diabetes Care 2003; 26 (8): 2305-2310
22. Rømming Sørensen V, Schwartz Sørensen S, Feldt-Ras-mussen B. Long-term graft and patient survival following renal transplantation in diabetic patients. Scand J Urol Nephrol 2006; 40: 247-251
23. Deutsche Stiftung Organtransplantation. Organtransplant-ationen in Deutschland einschlieXlich Lebendspender-Transplantation. Berlin: Deutsche Stiftung Organtrans-plantation, 2006
24. Frei U, Schober-Halstenberg H. Nierenersatztherapie in Deutschland. Berlin: QuaSi-Niere gGmbH, 2004
25. Adler A, Stevens R, Manley S, et al. Development and progression of nephropathy in type 2 diabetes (UKPDS 64). Kidney Int 2003; 63: 225-232
26. Schaufler TM. Volkswirtschaftlicher Nutzen medizinischer Fruhdiagnostik. Hamburg: Dr Kovac, 2007
27. Statistisches Bundesamt. Sterbetafeln 2002/2004. Wiesba-den: Statistisches Bundesamt, 2005
28. Roper N, Bilous R, Kelly W, et al. Cause-specific mortality in a population with diabetes: South Tees Diabetes Mortality Study. Diabetes Care 2002; 25: 43-48
29. Knowler W, Barrett-Connor E, Fowler S, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403
30. UK Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853
31. Harris M, Klein R, Welborn T, et al. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care 1992; 15: 815-819
32. Colagiuri S, Cull CA, Holman RR. Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes? UK Prospective Diabetes Study 61. Diabetes Care 2002; 25 (8): 1410-1417
33. Coffey J, Brandle M, Zhou H, et al. Valuing health-related quality of life in diabetes. Diabetes Care 2002; 25: 2238-2243
34. Herman W, Hoerger TJ, Brandle M, et al. The cost-effec-tiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med 2005; 142 (5): 323-332
35. Kassenarztliche Bundesvereinigung. EBM 2000plus Stand 2006 4. Quartal [database; archives no. 1003751399; online]. Available from URL: http://daris.kbv.de/daris.asp [Accessed 2009 Jul 1]
36. Rote Liste Service GmbH. Rote Liste [online]. Available from URL http://www.rote-liste.de [Accessed 2006 Nov 1]
37. Liebl A, Neiss A, Spannheimer A, et al. Kosten des Typ-2-Diabetes in Deutschland. Ergebnisse der CODE-2-Studie. Dtsch Med Wochenschr 2001; 126: 585-589
38. Weber C, Neeser K, Wenzel H, et al. Cost of type 2 diabetes in Germany over 8 years: the Rosso study no. 2. J Med Econ 2006; 9: 45-53
39. Kolominsky-Rabas P, Heuschmann P, Marschall D, et al. Lifetime cost of ischemic stroke in Germany: results and national projections from a population-based stroke registry. The Erlangen Stroke Project. Stroke 2006; 37: 1179-1183
40. Nagel E, Niechzial M. Bewertung chirurgischer Thera-pien: angemessen-notwendig-zweckmaXig. Berlin: Springer, 1999
41. Bundesversicherungsamt. Risikostrukturausgleich-Jahre-sausgleich 2005. Auswertungen. Bonn: BVA, 2006
42. Koster I, Ferber L, Hauner H. Die Kosten des Diabetes mellitus. Koln: PMV Forschungsgruppe, 2005
43. Stock S, Redaelli M, Wendland G, et al. Diabetes-prevalence and cost of illness in Germany: a study evalu-ating data from the statutory health insurance in Germany. Diabet Med 2006; 23: 299-305
44. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: NICE, 2004
45. Lipscomb J, Weinstein MC, Torrance GW. Time preference. In: Gold MR, Siegel JE, Russell LB, et al., editors. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996: 214-246